PR

ProGen, Co,, LTD.

Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.

296160 | KO

Overview

Corporate Details

ISIN(s):
KR7296160005
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙로 172, 6층, 7층, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ProGen is a clinical-stage biotechnology company focused on the research and development of innovative therapeutics. The company specializes in creating protein-based immunotherapies through its proprietary Neo Tri-ImmunoGlobulin (NTIG) platform, a next-generation technology for developing multi-specific fusion proteins and antibody treatments. ProGen's pipeline primarily targets metabolic diseases, immune disorders, and cancer. The company's business model is centered on platform-based drug discovery and pursuing global partnerships for late-stage clinical development and commercialization of its long-acting biologics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 65.8 KB
2025-08-18 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 24.2 KB
2025-08-18 00:00
Regulatory News Service
지정자문인선임계약의변경
Korean 5.1 KB
2025-07-15 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-07-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 99.0 KB
2025-07-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 122.5 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-06-11 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 16.7 KB
2025-06-11 00:00
Remuneration Information
[기재정정]주식매수선택권부여에관한신고
Korean 42.2 KB
2025-06-11 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 25.8 KB
2025-05-28 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 43.5 KB
2025-05-23 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 123.5 KB
2025-05-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-05-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB

Automate Your Workflow. Get a real-time feed of all ProGen, Co,, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ProGen, Co,, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ProGen, Co,, LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ANAVEX LIFE SCIENCES CORP. Logo
Developing precision therapeutics for neurodegenerative and CNS disorders.
United States of America
AVXL
Anbio Biotechnology Logo
Develops and supplies in vitro diagnostic solutions for human and veterinary markets.
United States of America
NNNN
Anebulo Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing an antidote for acute cannabinoid intoxication in ER patients.
United States of America
ANEB
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan
4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom
ANCR
ANI PHARMACEUTICALS INC Logo
Develops, manufactures, and markets branded/generic drugs and OTCs for niche therapeutic areas.
United States of America
ANIP
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden
ANNX
Annexon, Inc. Logo
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea
065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania
ATB

Talk to a Data Expert

Have a question? We'll get back to you promptly.